Scientists test 'Living Drug' designed to hunt down a Patient's own cancer
NCT ID NCT04520711
Summary
This early-stage trial is testing a personalized treatment for people with advanced cancers that cannot be cured. Doctors take a patient's own immune cells, genetically engineer them to better recognize their specific cancer, and infuse them back. These 're-trained' cells are given alongside two other drugs (pembrolizumab and CDX-1140) designed to boost the immune attack. The main goal is to see if this combination is safe, and a secondary goal is to see if it can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT EPITHELIAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.